VIRMA (Vir-like m6A methyltransferase associated protein), also known as KIAA1429, is a key component of the m6A methyltransferase complex that catalyzes N6-adenosinen methylation (m6A) of messenger RNA. This epigenetic modification is the most abundant internal modification in eukaryotic mRNA and plays critical roles in RNA splicing, stability, translation, and cellular localization . Recent research has revealed connections between VIRMA dysfunction and neurodegenerative disease mechanisms, particularly through its role in RNA metabolism and neuronal function.
The m6A epitranscriptome has emerged as a fundamental regulatory layer in gene expression, with dysfunction linked to Alzheimer's disease , Parkinson's disease , and amyotrophic lateral sclerosis . VIRMA serves as a critical scaffold within the m6A writer complex, making it a potential therapeutic target for neurodegenerative conditions.
¶ Gene and Protein Structure
The human VIRMA gene (KIAA1429) is located on chromosome 5q21.1 and encodes a protein of 1,593 amino acids with a molecular weight of approximately 174 kDa. The gene contains multiple functional domains:
- N-terminal region: Contains a zinc finger domain involved in RNA binding
- Central region: Harbors the methyltransferase-like domain
- C-terminal region: Contains disordered regions important for protein-protein interactions
The gene is ubiquitously expressed with highest levels in brain tissue, particularly in neuronal populations. Alternative splicing generates multiple isoforms with tissue-specific expression patterns.
¶ Protein Domains
VIRMA contains several functional domains:
- Zinc finger C3H1-type (ZnF): RNA recognition and binding, mediates interaction with specific RNA sequences
- Methyltransferase-like domain: Catalytic activity for m6A deposition, although VIRMA lacks catalytic activity itself, it organizes the active site
- Proline-rich region: Protein interaction motifs, facilitates binding with other writer complex components
- Low-complexity regions: Disorder prediction suggests regulatory functions in stress granule formation and phase separation
VIRMA is a core component of the m6A methyltransferase complex, often referred to as the "m6A writer" or MACET (m6A methyltransferase complex). The complex consists of:
| Component |
Gene |
Function |
| METTL3 |
METTL3 |
Catalytic subunit (SAM-dependent methyltransferase) |
| METTL14 |
METTL14 |
RNA-binding subunit, structural support |
| WTAP |
WTAP |
Regulatory subunit, nuclear localization |
| VIRMA/KIAA1429 |
VIRMA |
Scaffold protein, substrate recognition |
| RBM15/15B |
RBM15 |
RNA-binding, recruitment |
| ZC3H13 |
ZC3H13 |
Nuclear localization and stability |
VIRMA plays a unique structural role within this complex, acting as a molecular scaffold that positions the catalytic subunits METTL3 and METTL14 relative to their RNA substrates . This positioning is critical for the tissue-specific and transcript-specific patterns of m6A deposition observed in different biological contexts.
Recent studies have identified a subcomplex termed MACERT (m6A methyltransferase complex related to transformers) that specifically mediates m6A deposition in specific cellular contexts:
- VIRMA serves as the scaffold organizing the complex
- Directs the complex to specific target RNAs through interaction with sequence-specific RNA-binding proteins
- Regulates tissue-specific m6A patterns through differential expression of VIRMA isoforms
VIRMA facilitates m6A deposition through several mechanisms:
- Substrate recognition: VIRMA contains RNA-binding domains that direct the complex to specific transcript features, including stop codonproximal regions and long 3' UTRs
- Complex stabilization: VIRMA interactions with WTAP and METTL14 stabilize the entire writer complex in the nucleus
- Co-transcriptional deposition: VIRMA associates with RNA polymerase II during transcription, allowing m6A deposition co-transcriptionally
N6-methyladenosine (m6A) is the most prevalent internal modification in messenger RNA. This reversible epigenetic mark influences:
- RNA splicing: Alternative splicing regulation via YTHDC1
- RNA stability: Decay regulation via YTHDF2 - m6A-marked transcripts are targeted for rapid degradation
- Translation efficiency: Translation control via YTHDF1/eIF3 - m6A enhances translation initiation
- Nuclear export: RNA trafficking via YTHDC1 - m6A facilitates mRNA export from nucleus to cytoplasm
The "epitranscriptome" refers to the complete landscape of m6A modifications across all cellular RNAs. Key features:
- Approximately 25% of transcripts contain at least one m6A site
- Modified transcripts tend to have longer 3' UTRs
- m6A is enriched near stop codons and in long internal exons
- Tissue-specific m6A patterns regulate cellular identity and function
- Dynamic regulation in response to cellular stress and signaling events
¶ Writers, Erasers, and Readers
The m6A modification system involves three key component groups:
Writers (m6A methyltransferases):
- METTL3: Catalytic core
- METTL14: RNA-binding and structural support
- WTAP: Regulatory subunit
- VIRMA: Scaffold and substrate specificity
Erasers (m6A demethylases):
- FTO: First discovered m6A eraser, implicated in obesity and neuronal function
- ALKBH5: Nuclear demethylase, regulates mRNA export
Readers (m6A recognition proteins):
- YTHDF family (DF1, DF2, DF3): Cytoplasmic readers
- YTHDC family (DC1, DC2): Nuclear readers
- Other RBPs that recognize m6A-modified RNA
VIRMA-mediated m6A deposition regulates alternative splicing through multiple mechanisms:
- Splice site selection: m6A marks influence spliceosome recruitment to alternative splice sites
- Exon skipping: VIRMA activity affects inclusion/exclusion of alternatively spliced exons through YTHDC1-mediated mechanisms
- Alternative polyadenylation: m6A influences poly(A) site selection, affecting 3' UTR length and regulatory potential
¶ RNA Stability and Decay
VIRMA-dependent m6A marks serve as docking sites for reader proteins:
- YTHDF2: Directs transcripts to decay pathways - VIRMA-modified mRNAs can be rapidly degraded
- YTHDF1: Promotes translation of marked transcripts - VIRMA targets enable enhanced protein synthesis
- YTHDC1: Nuclear reader involved in splicing and export - mediates nuclear processing of VIRMA-modified RNAs
m6A modification influences subcellular RNA localization through:
- Nuclear export facilitation via YTHDC1
- Cytoplasmic trafficking to specific cellular compartments
- Localized translation in neuronal processes - critical for synaptic function
Recent studies have revealed significant connections between VIRMA dysfunction and Alzheimer's disease pathogenesis :
Amyloid Processing Regulation:
- m6A modification regulates amyloid precursor protein (APP) mRNA stability and translation
- VIRMA-mediated m6A deposition affects BACE1 expression levels
- Alterations in m6A patterns correlate with amyloid plaque burden
Tau Pathology:
- m6A modification influences tau kinase and phosphatase expression
- VIRMA activity affects alternative splicing of tau isoforms
- m6A reader proteins show altered expression in tauopathy
Synaptic Dysfunction:
- Synaptic plasticity requires precise RNA metabolism regulated by m6A
- VIRMA targets include key synaptic proteins including NMDA and AMPA receptor subunits
- Memory consolidation involves activity-dependent m6A modifications
Neuroinflammation:
- Microglial activation states are regulated by m6A epitranscriptomics
- VIRMA-mediated modifications affect cytokine and chemokine expression
- Therapeutic targeting of m6A pathways modulates neuroinflammation
Connections between VIRMA and Parkinson's disease have been identified through multiple mechanisms :
Alpha-Synuclein Regulation:
- Alpha-synuclein mRNA contains predicted m6A modification sites
- VIRMA activity may influence SNCA expression levels
- m6A modifications affect protein aggregation propensity
Mitochondrial Function:
- Mitochondrial RNA modifications are critical for energy metabolism
- VIRMA targets mitochondrial transcripts encoded in nuclear DNA
- Parkin and PINK1 expression influenced by m6A pathways
Dopaminergic Neuron Vulnerability:
- Specific vulnerability of substantia nigra neurons involves RNA metabolism defects
- VIRMA expression is altered in PD brain tissue
- LRRK2 mutations affect m6A modification patterns
RNA metabolism defects are a hallmark of ALS, and VIRMA plays a role in this context :
TDP-43 Pathology Intersection:
- TDP-43 aggregates are present in >95% of ALS cases
- TDP-43 regulates alternative splicing of m6A-related genes
- VIRMA expression is altered in TDP-43 proteinopathy
RNA Processing Defects:
- ALS-associated mutations affect RNA splicing factors
- VIRMA-mediated m6A patterns are disrupted in motor neurons
- Translation dysregulation contributes to proteostasis failure
A landmark study demonstrated that VIRMA plays a critical role in photoreceptor cell function through m6A modification :
Key Findings:
- VIRMA is highly expressed in retinal photoreceptors
- Loss of VIRMA leads to progressive retinal degeneration
- m6A modification is essential for phototransduction gene expression
- VIRMA deficiency causes misregulation of genes involved in visual cycle
The photoreceptor-specific functions of VIRMA include:
- Phototransduction cascade regulation: m6A modification of rhodopsin and related transcripts
- Visual cycle support: Regulation of genes involved in retinoid metabolism
- Outer segment maintenance: Control of proteins required for disc membrane turnover
- Circadian regulation: Connections to circadian clock gene expression
The retinal degeneration findings have important implications for understanding broader neurodegenerative mechanisms:
- Photoreceptors and neurons share common vulnerability mechanisms
- m6A-dependent RNA regulation is essential for neuronal survival
- VIRMA dysfunction may represent a common pathway in neurodegeneration
VIRMA represents a potential drug target for multiple conditions:
Small Molecule Inhibitors:
- Targeting VIRMA-RNA interactions to modulate m6A patterns
- Allosteric modulators of the writer complex
- Selectively modulating disease-specific m6A signatures
RNA-Based Therapies:
- Antisense oligonucleotides modifying m6A patterns on specific transcripts
- m6A-modified mRNA therapeutics to restore protein expression
- siRNA approaches to modulate VIRMA expression
Gene Therapy:
- AAV-mediated VIRMA expression restoration
- CRISPR-based epigenetic editing of m6A sites
- Gene replacement strategies for loss-of-function mutations
VIRMA activity and m6A patterns may serve as:
- Biomarkers for disease progression in AD, PD, and ALS
- Indicators of therapeutic response to disease-modifying treatments
- Predictors of treatment outcomes in personalized medicine approaches
¶ Challenges and Considerations
Several challenges must be addressed for therapeutic targeting of VIRMA:
- Complexity of m6A biology: The epitranscriptome has pleiotropic effects on cellular function
- Tissue-specific delivery: Brain delivery remains challenging for small molecules
- On-target toxicity: Global disruption of m6A may have adverse effects
- Biomarker development: Clinical validation of m6A-based biomarkers is needed